<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AE7EA01F-0FBC-454A-9BBC-762E455AC90B"><gtr:id>AE7EA01F-0FBC-454A-9BBC-762E455AC90B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Emrys</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/32D9E0C9-1B3A-4867-9B00-C61C58E93F9D"><gtr:id>32D9E0C9-1B3A-4867-9B00-C61C58E93F9D</gtr:id><gtr:firstName>Derek</gtr:firstName><gtr:surname>Mann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1CCF7D54-1A67-4035-A9C6-32E6B80824A4"><gtr:id>1CCF7D54-1A67-4035-A9C6-32E6B80824A4</gtr:id><gtr:firstName>Jelena</gtr:firstName><gtr:surname>Mann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0A0DE806-2BAC-4CEC-BD38-781D63A5F50B"><gtr:id>0A0DE806-2BAC-4CEC-BD38-781D63A5F50B</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Oakley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK001949%2F1"><gtr:id>46E050C0-898C-4025-A157-AB4462A803A3</gtr:id><gtr:title>MICA: Illuminating mechanisms regulating the birth, life and death of the myofibroblast to inform the development of antifibrotics for liver disease.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K001949/1</gtr:grantReference><gtr:abstractText>The ability of our bodily tissues to effectively repair cellular damage caused by environmental agents (viruses, bacteria, toxins, dietary factors etc) is critical for prevention of further damage or infection and for the healthy restoration of organ function. Key to tissue repair is the formation of temporary scars and contraction of wounds in order to &amp;quot;wall off&amp;quot; sites of damage while tissue healing takes place. If tissues suffer repeated damage over extended periods of time then scars are modified such that they are more difficult to break down during healing and they can spread to affect other parts of the organ. This is known as &amp;quot;fibrosis&amp;quot; and it can progress to the stage where the normal architecture and function of an organ is transformed to such an extent that it fails and the only current treatment options are transplantation or palliative care. Ageing appears to reduce the ability of organs to repair normally and as a result fibrosis is becoming more common in the general population, with recent estimates suggesting it underlies up to 40% of all deaths in the developed world. At present we have no proven effective therapies or preventative treatments for tissue fibrosis in any organ system. The liver is the organ responsible for detoxification and plays a major role in clearance of pathogens, however cells in the liver are equally susceptible to damage and infection as those in other parts of the body. As a consequence the liver is particularly susceptible to fibrosis where toxins or pathogens persist, and as we age when the regenerative capacity of the liver begins to falter. Chronic liver disease is currently the only common cause of death that is on the rise in the UK, with 16,000 deaths reported in 2008 and worryingly the trend is towards disease developing in people in their middle-life years. An effective antifibrotic that halts the development of scars and/or that helps break down existing scars in the liver would have a major impact on morbidity and mortality in patients with chronic liver disease. 

The research proposed in this application for a 5-year grant will build on work in the laboratory of the PI and his team that has identified a specialised cell in the diseased liver that promotes the formation, maintenance and spread of scars. This cell is known as a liver myofibroblast and it is generated chiefly by alterations in the properties and behaviour of liver cells that normally function to store Vitamin A. Upon injury or infection these so called &amp;quot;hepatic stellate cells&amp;quot; transform into myofibroblasts that produce vast quantities of scar tissue and are able to proliferate and migrate to cause fibrosis in the liver. The PI has been part of an international research effort that has confirmed that manipulating hepatic stellate cell-derived myofibroblasts can halt and even reverse fibrosis. The challenge for the next 5 years that will be tackled by the research team is to illuminate biochemical signals that regulate myofibroblast fate and function with the aim of finding biochemical &amp;quot;Achilles heels&amp;quot; that can be manipulated to stop or even hopefully reverse fibrosis. The research will use a combination of human cell culture, relevant mouse disease model systems and diseased human liver tissues to identify which signals can be manipulated to bring about antifibrotic effects. The team will use this knowledge to look for either existing drugs or new compounds (by chemical library screening) to find safe and effective treatments. This ambitious goal will be facilitated by a strong working partnership between the research team and the global biopharmaceutical company GlaxoSmithKline (GSK), the latter having a dedicated team of 40+ scientists working on discovery and development of antifibrotics at its Stevenage site. GSK will lend support with manpower, access to specialised scientific knowhow and provision of compounds and research tools as well as providing routes for translation to the clinic.</gtr:abstractText><gtr:technicalSummary>The research will employ the following methodologies in order to meet the stated aims and objectives in the &amp;quot;Case for Support&amp;quot;.

1. Human primary liver myobroblasts. These cells will be used to determine mechanisms by which epigenetic and transcription pathways influence fibrogenesis. The cells will be isolated from the normal margins of liver tissue resected for the removal of secondary tumours provided by liver surgeons (Profs White and Mannas) at the Newcastle NHS Trust Freeman Hospital. Isolated cells will be purified by density centrifugation and cultured in serum-containing media. 

2. A human myofibroblast cell line, LX2, will be used where high numbers of myofibroblasts are required for detailed studies such as chromatin immunoprecipitation, or where there is a need to modulate the expression of genes under study by transfection-based approaches. The LX2 line was generated in the laboratory of Prof Scott Friedman and is highly representative of the fibrogenic phenotype of primary liver myofibroblasts.

3. Archived paraffin-embedded diseased human liver tissue will be used for immunohistochemical detection of key regulatory proteins identified during the research as important to validate in human diseased tissue. The tissue is managed by the Newcastle University and NHS Trust Biobank and will be supplied as anonymised liver slide sections, with the original tissue blocks being retained by the Biobank.

4. Genetically modified mice (C57/Bl6) for key fibrogenic regulators such as MeCP2 and JunD will be used for supply of myofibroblasts in which these genes are either deleted or mutated into functionally attenuated forms, these studies enabling gene function to be examined with a high degree of confidence. The mice will also be employed in animal models of liver disease.</gtr:technicalSummary><gtr:potentialImpactText>The main beneficiaries from the research will be:

1. General public stakeholders associated with the MRC strategic themes of &amp;quot;Ageing&amp;quot; and &amp;quot;Lifelong Health and Wellbeing&amp;quot;. 
Fibrosis can occur in almost every soft tissue organ and impacts directly on fitness/vitality or in the worst cases leads to organ failure. Estimates suggest that 40% of all deaths in the developed world have fibrosis as an underlying contributory pathology. Although fibrosis is seen in young adults (in particular for liver disease) it is an age-associated pathology. Furthermore, the age of onset of chronic disease is a strong prognostic indicator for progression to fibrosis. With the average lifespan of UK people increasing each year fibrotic disease and its impact on quality of life and economic burden will be substantive. There is therefore an unmet need for drugs that will prevent progressive fibrosis which would benefit thousands of UK patients. With previous MRC funding the PI and the research team have delivered discoveries that have translated into (i) An EME-funded multi-centre clinical trial led by Prof Day (Newcastle) assessing the efficacy of losartan in non-alcoholic fatty liver disease (ii) Identification of 5-HT2B antagonists as antifibrotics in the liver expected to lead into clinical studies. It is anticipated that with continued MRC support and through partnership with GSK, the Mann laboratory will make further discoveries for clinical translation and ultimately leading to safe and effective antifibrotics. 

2. Academic/private sector collaboration and future benefits for economy. 
An effective antifibrotic will create a multi-billion pound worldwide market. Fibrosis is therefore now a key disease theme in the pharmaceutical and biotech industry, as evidenced by the recent establishment of a GSK fibrosis DPU at Stevenage. Mann and Oakley lead a Newcastle partnership with GSK to deliver antifibrotics in liver and kidney disease. Two of the major GSK drug leads (under disclosure agreements) in development emerged directly from MRC-funded work in the Mann lab carried out in the past 3 years. Mann also has PhD studentships for fibrosis-related projects with two biotech companies (Medimmune and UCB) which are helping to inform these companies on their future strategic investment in fibrosis. There is therefore strong evidence for a significant competitive advantage for UK industry in having first exposure to new fibrosis drug targets emerging from the high quality MRC-funded research emerging from the Mann laboratory. 

3. International academic colleagues working in chronic disease and fibrosis. 
The PI is widely considered to be a world leader in the emerging field of tissue fibrosis. Published discoveries, international conference presentations of work on mechanisms of liver fibrosis and provision of research tools and concepts from the Mann lab have combined to stimulate research across the globe to find evidence of similar fibrogenic mechanisms in other organ systems (lung, skin, kidney and eye). This has led to the identification of core fibrogenic targets for drug discovery and has raised the worldwide academic profile of fibrosis research. This impact is expected to expand if the Newcastle team are funded with their first programme-level grant.

4. Postdoctoral Scientists funded on the grant.
The PI has mentored the career development of three postdoctoral scientists (Oakley, J Mann and Prof Matt Wright) to senior academic posts and each is now emerging as international leaders in the fibrosis field. The Mann lab is currently comprised of trainee researchers from the UK, Spain, Australia, India, Turkey, Germany and past lab members now hold postdoctoral or industry posts in the USA, Australia and Europe. The lab is therefore a high quality environment for training and career development and this will be of direct benefit to postdoctoral and PhD student scientists working on the research programme.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-02-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-02-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1553839</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Biology GSK</gtr:department><gtr:description>CRAFT collaboration</gtr:description><gtr:id>1E805277-594F-499E-BF82-362A2EAB24FC</gtr:id><gtr:impact>Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease.
Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T, Masson S, Mathers JC, French J, White S, Mann J.
Clin Epigenetics. 2015 Mar 14;7(1):25. doi: 10.1186/s13148-015-0056-6. eCollection 2015.</gtr:impact><gtr:outcomeId>5601193902d6f2.26376091-1</gtr:outcomeId><gtr:partnerContribution>GSK have provided funding and some technical advice.</gtr:partnerContribution><gtr:piContribution>The partnership is aimed at developing transcriptional and epigenetic biomarkers that help predict progression of fibrosis in chronic lung and liver diseases. Our team is extracting DNA from fibrotic tissue by laser capture microscopy or from plasma and then quantifying DNA methylation at specific loci which we have shown to be differentially methylated as part of MRC-funded research.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AbbVie</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Identification of liver fibrosis patients</gtr:description><gtr:id>C5A5C1F4-D7CB-49B5-9F89-45B78A0C707B</gtr:id><gtr:impact>None at this time</gtr:impact><gtr:outcomeId>56bc5f26da0399.19078610-1</gtr:outcomeId><gtr:partnerContribution>The partner ha provided funding and contributed to design of the experimental plan and project management</gtr:partnerContribution><gtr:piContribution>We will exploit our development of laser-capture microscopy, next generation sequencing, DNA methylation profiling and access to a unique resource of paired biopsy samples from patients with non-alcoholic fatty liver disease to develop novel biomarkers for the identification of patients who are at most risk of progressing to fibrosis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Discovery of differential DNA methylation markers in sperm resulting from liver fibrosis</gtr:description><gtr:id>EEA7DBDB-B8DC-4918-9484-362C8DF9A8E6</gtr:id><gtr:impact>None to date, data still being collected and analysed.</gtr:impact><gtr:outcomeId>56011a84419af5.00376545-1</gtr:outcomeId><gtr:partnerContribution>Novartis have carried out extensive methylation and hydroxymethylation sequencing, quantification and bioinformatics</gtr:partnerContribution><gtr:piContribution>The project aims to discover sites of differential DNA methylation in rat sperm that are modulated in response to development of liver fibrosis and which may function as conduits for generational transmission of heritable epigenetic traits. Our team has provided a rodent model of transgenerational inheritance and more specifically sperm from animals that have undergone an epigenetic adaption to liver fibrosis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AbbVie</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Development of model systems for the identification of fibrosis mechanisms in non-alcoholic fatty liver disease (NAFLD)</gtr:description><gtr:id>CCAC21CC-EE84-484F-A031-42DC1C345361</gtr:id><gtr:impact>None at this stage</gtr:impact><gtr:outcomeId>56bc60d2b5d6b8.79095854-1</gtr:outcomeId><gtr:partnerContribution>Funding only</gtr:partnerContribution><gtr:piContribution>This collaboration will address three project aims:

1. To develop a novel in-house precision cut liver slice bioreactor system for developing a human model of NAFLD.
2. To develop a hanging-drop culture system for studying cell-cell interactions in human NAFLD.
3. To exploit a novel rodent model of epigenetic adaption to liver fibrosis for discovering novel fibrosis-regulating pathways.

My team will perform all experimental investigations, bioinformatic analyses, data analyses and presentations.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>10th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (Sao Paulo, Brazil)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80C34B8B-D090-4FE4-B24F-E154B85D5DBE</gtr:id><gtr:impact>This is an international symposium aimed at dissemination of research discoveries in the fields of alcoholic liver and pancreatic diseases. I was invited to give a 20 minute talk on &amp;quot;Epigenetic regulation of liver fibrosis&amp;quot; in the session &amp;quot;Cutting Edge of Liver Fibrosis&amp;quot;, this was followed by a lively 10 minute discussion.</gtr:impact><gtr:outcomeId>56bc7d29ce1504.65692457</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://keck.usc.edu/en/Research/Centers_and_Programs/Research_Center_For_Alcoholic_Liver_and_Pancreatic_Disease/~/media/Docs/Research/Centers%20and%20Programs/ALPD/10thALPDprogrammeOctober%202014.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>50th Annual Congress of the European Association for the Study of the Liver (EASL)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F07E612-C62A-48F4-997F-A7829E9B41A5</gtr:id><gtr:impact>The EASl International Liver Congress is an annual event attended by around 9,000 participants. I was invited to present our work on the role of inflammation as a driver of liver cancer which i co-presented with a postdoctoral student (Dr Caroline Wilson) from my team.</gtr:impact><gtr:outcomeId>56bc79bcd66204.92922438</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCB Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EBAD7D61-9A7C-4C86-BE99-3AD3F0EBCE43</gtr:id><gtr:impact>I presented a talk to the company UCB based in Slough, England. The talk was entitled &amp;quot;Epigenetic Regulation of Fibrosis&amp;quot;, lasted 40 minutes and was followed up by a 20 minute question and answer session.</gtr:impact><gtr:outcomeId>56bc701b8ecec1.54209316</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>11th International Meeting on Therapy in Liver Disease, Barcelona.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>120CDD95-EE1E-4081-A121-8E1367959609</gtr:id><gtr:impact>This was an educational meeting aimed at disseminating state-of-the-art information on liver diseases to an international audience of hepatologists (principally clinicians). I was invited to present a broad-reaching talk on &amp;quot;Novel antifibrotic strategies in chronic liver diseases&amp;quot; in the session entitled &amp;quot;hot topics in clinical hepatology&amp;quot;.</gtr:impact><gtr:outcomeId>56bc7bbf5ddf94.01096226</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.viajesoasis.com/es/liver/PROGRAMA.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Immunology</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EC4E48A-F317-4CA0-9E26-0314C023669E</gtr:id><gtr:impact>This was the annual BSI summer school held in 2013 at Newcastle University. I presented a 45min talk on the topic of chronic inflammation. The event was attended by postgraduate students, postdoctoral scientists and senior scientists from the UK and overseas.</gtr:impact><gtr:outcomeId>56bc6e0dc568e0.38395044</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://immunology.org/events--meetings/summer-school-2013/--bsi-events--meeting-summer-school-2013---speakers</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>leading edge 2013 - love your liver</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BDCD9B3A-5728-484B-A9B3-3305DC574102</gtr:id><gtr:impact>Eighty school children participated in leading edge this year. they attend a series of workshops from scientific skills, communication skills and lab visits to experience &amp;quot;real research&amp;quot;. The students presented their project at a grand finale event and the British Science festival. 
Six of these students undertook a liver project with myself.

yes - requests for work experiences/shadowing or lab visits for schools and sixth for are facilitated by the institute and fibrosis lab.</gtr:impact><gtr:outcomeId>hPyxT8nDMkG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://research.ncl.ac.uk/fibrosislab/newsevents/publicengagement/leadingedge/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FASEB Liver Biology Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FB526125-CA54-4800-A10D-881920DE3147</gtr:id><gtr:impact>This is a biannual meeting at which research advances in liver cell biology are presented to an audience of hepatologists (clinical and basic scientists). I presented a 30 min talk on 'Epigenetic control of Liver Fibrosis&amp;quot; which was followed by a 10 min question and answer session.</gtr:impact><gtr:outcomeId>56bc76165a2e19.24741095</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>love your liver</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>92996709-E7A0-452F-8137-E1BB4F247503</gtr:id><gtr:impact>60 pupils attended an interactive workshop

The institute are now hosting work shadowing/experience from local schools and sixth form colleges.</gtr:impact><gtr:outcomeId>qHJcE9KCeox</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ncl.ac.uk/icm/public/school/science/index.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Association for Study of Liver Disease Annual Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>96B053D4-5624-4B18-BF1C-383228EC4CF4</gtr:id><gtr:impact>I was invited to provide an educational seminar on &amp;quot;Epigenetic regulation of hepatic stellate cell activation&amp;quot; as part of the AASLD meeting syllabus.</gtr:impact><gtr:outcomeId>56bc778f533bf0.20539852</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Scleroderma Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DC137248-B4CE-449C-9281-42FB9DB3C812</gtr:id><gtr:impact>An invited talk on &amp;quot;Epigenetic modifications as novel targets in tissue fibrosis&amp;quot; as part of a dedicated session &amp;quot;Epigenomics in Fibrosis&amp;quot;. I gave a 30 minute presentation followed by a 30 minute general discussion session where I answered a large number of questions in a very lively debate. As a direct consequence of this event discussions have been initiated with 2 biotech companies around future research.</gtr:impact><gtr:outcomeId>56bc74e9351ba2.84912536</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bumc.bu.edu/sclerodermaworkshop/files/2015/08/Programme-Cambridge-15.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Turkish Association for Study of Liver (TASL) Annual Meeting (Istanbul)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>50CD0E60-0AC6-4AEA-A9C4-1C0121FB4A92</gtr:id><gtr:impact>I was invited to the TASL meeting to present an educational talk on &amp;quot;Basic mechanisms and reversibility of liver fibrosis&amp;quot;.</gtr:impact><gtr:outcomeId>56bc7f4022f227.06829959</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research presentation to patients suffering from fibrosis in replacement knees</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>79BD88FC-C56B-4B1D-B539-085D9C70205F</gtr:id><gtr:impact>50 patients attended this meeting to be educated on the biology of fibrosis and how it affects their knee joint which for most of these patients had become stiff, painful and developed reduced mobility. Along with a surgeon (Prof David Deehan), a clinical fellow (Dr Nick Kalson) and a scientific fellow under my mentorship (Dr Lee Bothwick) we each made 15min long presentations which were then followed by a buffet tea and a very lively question and answer session. The entire meeting lasted 3hrs.</gtr:impact><gtr:outcomeId>56bc6b76d42c28.29610956</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>british science festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>949CDB9A-9BF2-4183-8D83-EE9F1981F57F</gtr:id><gtr:impact>four workshops over the course of the day. 20 school children took part in each workshops and leanred about liver disease

no</gtr:impact><gtr:outcomeId>PHHCfj8kdom</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.britishscienceassociation.org/british-science-festival</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research presentation to Liver North</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E480F652-CE6A-41F3-BAAA-A24C73288096</gtr:id><gtr:impact>LiverNorth is a well organised and well informed patient-ran charity that provides funding for liver disease resesrch and patient support in the North East of England. They have monthly meetings at which a basic or clinical research presenntation is provided by either a physician, scientist or surgeon. I presented the work my team has been carrying out on reversal of liver fibrosis.

Support letters from LiverNorth were provided for successful grant applications to the European Union and the MRC.</gtr:impact><gtr:outcomeId>01D67C1332B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>36th European Workshop for Rheumatology Research</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0D20B33F-28BA-4F34-BA7E-E584E16B803A</gtr:id><gtr:impact>I was invited to give a 30 minute talk on &amp;quot;epigenetic regulation of fibrosis&amp;quot;. Epigenetics is becoming an interesting pathology in rheumatology research yet they have few experts. My talk was aimed at educating junior investigators.</gtr:impact><gtr:outcomeId>56d80ff4354667.22880625</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.ewrr.org</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>18th International Symposium on Cells of the Hepatic Sinusoid (Asilomar, California)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2D88007A-7627-4AC8-9EFB-FC837B7AF11E</gtr:id><gtr:impact>This is a small focussed meeting dedicated to dissemination of recent research discoveries relating to cells that function within the liver sinusoid. I was invited to give a 20 minute presentation entitled &amp;quot;Role of Neutrophils in Hepatocellular Carcinoma&amp;quot;.</gtr:impact><gtr:outcomeId>56bc7e5b5bac11.48034796</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ischs2015.com</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NC3R workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F8F9421B-0D37-4AF2-94D2-1561DF87F88C</gtr:id><gtr:impact>presented a talk entitled &amp;quot;Modelling disease in organotypic precision cut slices using novel bioreactor technology&amp;quot; at the NC3Rs David Sainsbury Seminar Series: What is the future of 3Rs research? held at Newcastle University 11/10/2016</gtr:impact><gtr:outcomeId>58b5ba39043b32.72054171</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Turkish Society of Gastroenterology 30th National Gastroenterology Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>24E4BF69-184B-44B5-9EF6-32E082249306</gtr:id><gtr:impact>I gave a presentation on the &amp;quot;Cell and Molecular Regulation of Tissue Fibrosis and Epigenetic Control of Fibrosis&amp;quot;, the talk lasted 25 minutes and was followed by a 10 minute question and answer session</gtr:impact><gtr:outcomeId>56bc6f6fc9c724.68438745</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Workshop on Scleroderma Research</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C32B0F7-B7D2-4A3F-BBFB-4F02418D5D1B</gtr:id><gtr:impact>The workshop is an annual workshop event attended by postgraduate and postdoctoral students, senior investigators, industry, sponsors and patients. It is aimed at scientific education and research communications of relevance to scleroderma. I gave a presentation entitled &amp;quot;Epigenetics and liver fibrosis&amp;quot;</gtr:impact><gtr:outcomeId>56bc734e7bde30.07618109</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bumc.bu.edu/sclerodermaworkshop/files/2012/11/Booklet1.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Study of the Liver (BASL) Training Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F976823-7751-4D27-AD1F-D75769ED6044</gtr:id><gtr:impact>This was a training/educational event organised by BASL for basic science education of postgraduate students in the UK working in the field of liver biology and diseases.</gtr:impact><gtr:outcomeId>56bc785487f757.87628572</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ILSI HESI &quot;Advances in Assessing Adverse Epigenetic Effects of Drugs and Chemicals&quot; (Washington)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>83D34E62-496F-4A1A-BB59-23699EA91043</gtr:id><gtr:impact>International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) held a symposium entitled &amp;quot;Advances in Assessing Adverse Epigenetic Effects of Drugs and Chemicals&amp;quot; at which I was invited to discuss our research on &amp;quot;transgenerational epigenetic effects of toxin-induced chronic liver disease. This was a meeting at which there was a great deal of debate and discussion centred around opportunities to utilize epigenomic profiling for risk assessment of drugs and chemicals in the general population. A publication arose from the symposium.</gtr:impact><gtr:outcomeId>56bc948575ef58.58605005</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.sciencedirect.com/science/article/pii/S0300483X15300032</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>97200</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</gtr:department><gtr:description>NIH UO1 scheme</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>E6D8ECDB-F7F2-44BF-8581-39C21432791A</gtr:id><gtr:outcomeId>56bc681ff1c071.77635303</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This is a mouse in which a phosphor-modification (S100) regulating the AP-1 transcription factor JunD has been mutated. The mouse will be used to determine if this phosphorylation site is a potential target for drug development in inflammation and fibrosis.</gtr:description><gtr:id>154A7118-59D7-457A-A549-6D85AA0B0666</gtr:id><gtr:impact>Data collected so far suggest that this single site mutation leads to defective expression and induction of IL-6 in response to inflammatory mediators, if confirmed in further studies this will be of high significance to control of inflammation, fibross and cancer.</gtr:impact><gtr:outcomeId>56d80417866de7.39355650</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>JunDS100A mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Together with engineers at Newcastle University we have developed and secured IP on a novel 3D slice culture platform that allows us to maintain rodent or human liver slices intact and functional for at least 7 days, this is a significant advance on existing organotypic slice models. The 3D liver bioreactor is now being developed for modelling alcoholic and non-alcoholic fatty liver disease.</gtr:description><gtr:id>C15271D0-1380-4119-90BB-D32528220BFE</gtr:id><gtr:impact>The technology has attracted collaborative funding from GSK and Abbvie.</gtr:impact><gtr:outcomeId>56d80227e307b6.98616913</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>3D Liver Bioreactor</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This is a mouse in which the AP-1 transcription factor and Jun family member JunD is engineered with flox sites either side of the coding region to deliver entire knock out of the gene upon crossing of the animal with Cre expressing mice. We have confirmed that the mouse delivers JunD knockout by crossing to mice expressing Cre under the control of hepatocyte and fibroblast specific promoters. The mouse will be used to interrogate the function of JunD in specific cell types in diseased liver.</gtr:description><gtr:id>F08CD1C1-1971-4DEA-B622-D47E743C8CEE</gtr:id><gtr:impact>None at this stage</gtr:impact><gtr:outcomeId>56d803451915a7.09069873</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>JunDfl/fl mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have exploited a single chain antibody (C1-3) recognising an antigen called synaptophysin expressed on liver myofibroblasts to develop a new method of imaging fibrosis in live mice. The technology will enable us to more carefully monitor progression and regression of liver fibrosis and help determine the efficacy of anti-fibrotic drugs.</gtr:description><gtr:id>9C7DC62F-5C29-46E1-8A2A-379D7957B953</gtr:id><gtr:impact>A publication is in review with the Journal of Hepatology</gtr:impact><gtr:outcomeId>56d8053744d159.98623291</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Method for imaging liver fibrosis in vivo</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>At present the &amp;quot;gold standard&amp;quot; for determining fibrosis and disease progression in chronic liver disease is the liver biopsy which is a highly invasive process associated with discomfort for the patient, risk of internal bleeding and it suffers from sampling error. On the basis of our investigations into the epigenetic control of liver fibrosis we have discovered methylation signatures on the PPARgamma gene that are differentially modified in the population. Using a novel pyrosequencing assay we have shown that levels of DNA methylation at the PPARgamma gene can be used to detect fibrosis in patients and stratify their disease progression with great accuracy. Importantly we have been able to carry out this assay on cell-free DNA isolated from patient blood plasma.</gtr:description><gtr:id>391D0D47-8DF1-4A7B-8DC2-4335E9E04519</gtr:id><gtr:impact>The work has been accepted for publication in the journal GUT. 

The technology has been protected by patent application currently in review.</gtr:impact><gtr:outcomeId>56d80779773a05.55324978</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A blood-based epigenetic test for liver fibrosis</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D94AE17E-65A9-48A0-8B05-4B8ADF328A47</gtr:id><gtr:title>IL-1a released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6cfd91f59b8d8c64fab870754004afa"><gtr:id>d6cfd91f59b8d8c64fab870754004afa</gtr:id><gtr:otherNames>Suwara MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>pm_540e196e19606f943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C6E61EB-78CF-4CA4-87D4-EA123EFF9919</gtr:id><gtr:title>Emerging and disease-specific mechanisms of hepatic stellate cell activation.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47c22c613017a019cf2555ef1e581d4"><gtr:id>e47c22c613017a019cf2555ef1e581d4</gtr:id><gtr:otherNames>Wallace MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn><gtr:outcomeId>560113f389f6c0.50183826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC14CF52-84A5-4E93-8130-3F11CB89F5F9</gtr:id><gtr:title>Epigenetics in liver disease: from biology to therapeutics.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a848422476334f226f41304fa35a4435"><gtr:id>a848422476334f226f41304fa35a4435</gtr:id><gtr:otherNames>Hardy T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>585d3b33360d76.61928953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC78C3D4-6D59-445C-9757-1A34E5DF4C55</gtr:id><gtr:title>Mitochondria are required for pro-ageing features of the senescent phenotype.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc3e216bbe4afc1611d3f8d443f0cc45"><gtr:id>bc3e216bbe4afc1611d3f8d443f0cc45</gtr:id><gtr:otherNames>Correia-Melo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>58a49edd54a249.04684246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79EFBEC0-250F-444B-A9A8-4F24215ED748</gtr:id><gtr:title>Alcohol directly stimulates epigenetic modifications in hepatic stellate cells.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/693bafaf8d3b108c90f888efa19e64e3"><gtr:id>693bafaf8d3b108c90f888efa19e64e3</gtr:id><gtr:otherNames>Page A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>560113f2e00874.61417009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E346EAF-48CC-41A5-BB2A-CDD7023147A7</gtr:id><gtr:title>Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute.</gtr:title><gtr:parentPublicationTitle>Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89be9028229b48dc5bd6fcdd18ca8d28"><gtr:id>89be9028229b48dc5bd6fcdd18ca8d28</gtr:id><gtr:otherNames>Miousse IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-483X</gtr:issn><gtr:outcomeId>560113f3bb0657.77606798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85360326-DD85-42F0-AE34-5DE89315877E</gtr:id><gtr:title>Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27d36db19d0e467a6921245842cd030"><gtr:id>b27d36db19d0e467a6921245842cd030</gtr:id><gtr:otherNames>Wilson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>560113f423d484.84952562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>662307B3-5870-481C-8AE9-37F140B4D2A7</gtr:id><gtr:title>A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74b67d302f01664c5635d70bc831a2b2"><gtr:id>74b67d302f01664c5635d70bc831a2b2</gtr:id><gtr:otherNames>Moles A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_540e156e1564efa69</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B5E6EDA-72E1-4679-8582-51F3FE86325C</gtr:id><gtr:title>International consensus on the definition and classification of fibrosis of the knee joint.</gtr:title><gtr:parentPublicationTitle>The bone &amp; joint journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6f382ba3c579a64bfe6f3b69ec74052"><gtr:id>e6f382ba3c579a64bfe6f3b69ec74052</gtr:id><gtr:otherNames>Kalson NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2049-4394</gtr:issn><gtr:outcomeId>58a49cc3d00bf8.61782308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7B7E948-BFD0-49AA-A5BA-D4B02668CBB8</gtr:id><gtr:title>Non-Canonical Wnt Predominates in Activated Rat Hepatic Stellate Cells, Influencing HSC Survival and Paracrine Stimulation of Kupffer Cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f62ee00d8e2bdd4f978baf60253e933"><gtr:id>2f62ee00d8e2bdd4f978baf60253e933</gtr:id><gtr:otherNames>Corbett L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56bc57ffa5c150.33218531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AAA2600-BF8A-4676-95B3-F3C3A2A25314</gtr:id><gtr:title>A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-?B-dependent liver regeneration and cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74b67d302f01664c5635d70bc831a2b2"><gtr:id>74b67d302f01664c5635d70bc831a2b2</gtr:id><gtr:otherNames>Moles A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58a49e62066e46.21201470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>446010C5-E03B-49E0-8B0D-676BF55A4A69</gtr:id><gtr:title>NF?B1 is a suppressor of neutrophil-driven hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27d36db19d0e467a6921245842cd030"><gtr:id>b27d36db19d0e467a6921245842cd030</gtr:id><gtr:otherNames>Wilson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>doi_55faa1aa1cceee3f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77BA7899-7F3C-4212-9906-237E38C92DC0</gtr:id><gtr:title>Novel therapeutic targets in primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>560113f358f6d1.92369049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67700B97-D2B0-4D2C-808B-998FD76D70E7</gtr:id><gtr:title>Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27d36db19d0e467a6921245842cd030"><gtr:id>b27d36db19d0e467a6921245842cd030</gtr:id><gtr:otherNames>Wilson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e156e1565bd9e1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA87F5C6-EA2A-4622-9E64-60A6EB11A3AF</gtr:id><gtr:title>Fibroblasts Promote Inflammation and Pain via IL-1a Induction of the Monocyte Chemoattractant Chemokine (C-C Motif) Ligand 2.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05a28455d8dc1617213098f1b4a2ee75"><gtr:id>05a28455d8dc1617213098f1b4a2ee75</gtr:id><gtr:otherNames>Paish HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5a60b909caf630.43683932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7DA85E-3A2E-4B18-A4EC-6A6DD6280710</gtr:id><gtr:title>Variant Histone H2afv reprograms DNA methylation during early zebrafish development.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed16edfd94035bf4ed7ee2d4d61b1300"><gtr:id>ed16edfd94035bf4ed7ee2d4d61b1300</gtr:id><gtr:otherNames>Madakashira B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn><gtr:outcomeId>5a60b9097fb551.12142508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F8F2276-A482-48DA-8585-9D8925A3EC5F</gtr:id><gtr:title>Reduced telomere length is associated with fibrotic joint disease suggesting that impaired telomere repair contributes to joint fibrosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6f382ba3c579a64bfe6f3b69ec74052"><gtr:id>e6f382ba3c579a64bfe6f3b69ec74052</gtr:id><gtr:otherNames>Kalson NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a60b909ea6d34.70411579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C34CC563-7BF0-44D2-9836-A3A96FB98B8F</gtr:id><gtr:title>Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58a49ea2b24501.87313506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD58E98D-65B8-4379-836C-C2E0E88AD5B9</gtr:id><gtr:title>Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a848422476334f226f41304fa35a4435"><gtr:id>a848422476334f226f41304fa35a4435</gtr:id><gtr:otherNames>Hardy T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>58a49df46779d4.45558581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>713B5F33-82C9-4D2D-A8C7-3FA7ACEF2874</gtr:id><gtr:title>How reliable are sino-nasal cell lines for studying the pathophysiology of chronic rhinosinusitis?</gtr:title><gtr:parentPublicationTitle>The Annals of otology, rhinology, and laryngology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cef7aff0702ed1cdc1357bde8159954d"><gtr:id>cef7aff0702ed1cdc1357bde8159954d</gtr:id><gtr:otherNames>Ball SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4894</gtr:issn><gtr:outcomeId>560113f32513c1.65126374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6961C463-2FE8-4B9F-8254-604BA1E98423</gtr:id><gtr:title>Epigenetics in liver disease.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43b212cc245f89c717c6028051e87a2d"><gtr:id>43b212cc245f89c717c6028051e87a2d</gtr:id><gtr:otherNames>Mann DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5450fceb685774.47567481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6AF3426-7625-4E10-955D-DEEBA25E1893</gtr:id><gtr:title>Chronic inflammation induces telomere dysfunction and accelerates ageing in mice.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be2bfba42b3fd25c952e5310dad46c14"><gtr:id>be2bfba42b3fd25c952e5310dad46c14</gtr:id><gtr:otherNames>Jurk D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5422bc0f6edf93.30250031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487B5DBF-9D79-40AB-9D18-51DB6EAB9513</gtr:id><gtr:title>Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/031cd1754aad510570d89470b76ef670"><gtr:id>031cd1754aad510570d89470b76ef670</gtr:id><gtr:otherNames>Robinson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_14068_28_23624001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F849C9F8-6F56-4B86-BF25-68675668DE99</gtr:id><gtr:title>A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e503d6853ae389445c83e0bc10a26f"><gtr:id>49e503d6853ae389445c83e0bc10a26f</gtr:id><gtr:otherNames>Zeybel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58a49c78f0d282.64645983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D3428EE-2C8C-4614-A09F-E5B1DD9D18DB</gtr:id><gtr:title>Epigenetic reprogramming in liver fibrosis and cancer.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27d36db19d0e467a6921245842cd030"><gtr:id>b27d36db19d0e467a6921245842cd030</gtr:id><gtr:otherNames>Wilson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>5a60b90942f2b2.60494837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A937C6F3-4F63-4984-B44F-51157E8A4CC2</gtr:id><gtr:title>Epigenetic modifications as new targets for liver disease therapies.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e503d6853ae389445c83e0bc10a26f"><gtr:id>49e503d6853ae389445c83e0bc10a26f</gtr:id><gtr:otherNames>Zeybel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5450fd831230b1.96463148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D32A6EE1-6A9E-42BC-A7F1-D73B2222EDEC</gtr:id><gtr:title>Dynamic phosphorylation of RelA on Ser42 and Ser45 in response to TNFa stimulation regulates DNA binding and transcription.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6c3dc9b06146807744ae4d0476acbd5"><gtr:id>f6c3dc9b06146807744ae4d0476acbd5</gtr:id><gtr:otherNames>Lanucara F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>58a49d4137c090.00787350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>125315F5-370D-4B64-A1EA-81137AB8DFC3</gtr:id><gtr:title>Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease.</gtr:title><gtr:parentPublicationTitle>Clinical epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e503d6853ae389445c83e0bc10a26f"><gtr:id>49e503d6853ae389445c83e0bc10a26f</gtr:id><gtr:otherNames>Zeybel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1868-7075</gtr:issn><gtr:outcomeId>56bc5cf6636230.14832349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DC0E395-F93A-4A28-B190-7737C924DDE5</gtr:id><gtr:title>Cellular senescence drives age-dependent hepatic steatosis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3433d848b2841aeb74985dde198348c"><gtr:id>f3433d848b2841aeb74985dde198348c</gtr:id><gtr:otherNames>Ogrodnik M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a60b87a0f0e42.23528992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5C23FEA-9220-4AEA-A868-30D37336746D</gtr:id><gtr:title>Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f5ad466f939c0b0392cd79085389ec1"><gtr:id>3f5ad466f939c0b0392cd79085389ec1</gtr:id><gtr:otherNames>Perugorria MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_12438_28_23080298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95D180F7-873E-41B0-8C58-60F44EC26FF6</gtr:id><gtr:title>Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74b67d302f01664c5635d70bc831a2b2"><gtr:id>74b67d302f01664c5635d70bc831a2b2</gtr:id><gtr:otherNames>Moles A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_12438_28_22996371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D3923A9-66AD-43F1-88F9-D9ED3CA795FD</gtr:id><gtr:title>A potential mode of action for Anakinra in patients with arthrofibrosis following total knee arthroplasty.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a5404bb37d5b4a05cac321c05c9269a"><gtr:id>6a5404bb37d5b4a05cac321c05c9269a</gtr:id><gtr:otherNames>Dixon D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56bc5781807014.17225848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46BF8583-0781-4CB3-99B9-BCC8D30EA462</gtr:id><gtr:title>Joint Stiffness Is Heritable and Associated with Fibrotic Conditions and Joint Replacement.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4afcf07baa7afc67146a498a985e08a"><gtr:id>d4afcf07baa7afc67146a498a985e08a</gtr:id><gtr:otherNames>Williams FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>560113f3ea6809.38772245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D07AF84B-065B-4AB8-B75D-0784A646C695</gtr:id><gtr:title>Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/693bafaf8d3b108c90f888efa19e64e3"><gtr:id>693bafaf8d3b108c90f888efa19e64e3</gtr:id><gtr:otherNames>Page A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56bc5b8be87419.96450157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55B11E02-453B-4AE7-8A29-86D154858101</gtr:id><gtr:title>Epigenetic regulation of wound healing and fibrosis.</gtr:title><gtr:parentPublicationTitle>Current opinion in rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/122a3ac57004c739fb091b0635f582fc"><gtr:id>122a3ac57004c739fb091b0635f582fc</gtr:id><gtr:otherNames>Mann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-8711</gtr:issn><gtr:outcomeId>pm_12438_28_23114590</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K001949/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>